At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 26 enrolled
Drug / intervention
64Cu-PSMA I&Tdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Open-Label, Randomized Phase 2 Study of Copper Cu 64 PSMA I&T Injection in Patients With Histologically Proven Metastatic Prostate Cancer
In Brief
A Phase 2 clinical trial evaluating 64Cu-PSMA I&T for Metastasis From Malignant Tumor of Prostate (Disorder). Completed, enrolled 26 participants across 9 sites.
Detailed Summary
This is a prospective, open-label Phase 2 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with recurrent metastatic prostate cancer after radical prostatectomy or radiation therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2023202420252026
Enrollment StartDec 2022
First PostedDec 2022
Primary CompletionMay 2023
TodayJul 2026
First PostedDec 16, 2022
Enrollment StartDec 5, 2022
Primary CompletionMay 17, 2023
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 3.5 years ago
Interventions
64Cu-PSMA I&Tdrug
Radiolabeled Receptor-Targeted Diagnostic Product